C1-inhibitor autoantibodies in SLE

T. Mészáros, G. Füst, H. Farkas, L. Jakab, G. Temesszentandrási, G. Nagy, E. Kiss, P. Gergely, M. Zeher, Z. Griger, L. Czirják, R. Hóbor, A. Haris, K. Polner, L. Varga

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The presence of anti-C1-inhibitor (anti-C1-INH) autoantibodies is a hallmark of acquired C1-inhibitor deficiency. However, only scarce data are available on their prevalence, diagnostic value, and/or significance in systemic lupus erythematosus (SLE). In a multicentre study, we determined the levels of autoantibodies to C1-inhibitor in sera from 202 patients with SLE and 134 healthy controls. Additional clinical and laboratory parameters, such as organ involvement, as well as anti-C1q, anti-double-stranded DNA antibody, erythrocyte sedimentation rate, C-reactive protein, C3 and C4 serum complement levels have been studied in patients. The level of anti-C1-INH IgG was significantly higher (p = 0.034) in SLE patients, than in the controls. A high anti-C1-INH level of ĝ‰¥0.4 U/ml (mean of controls + 2 SD) was found in 17% of the patients, but in only 4% of the controls (p = 0.0003). The SLEDAI score was significantly higher (p = 0.048) and the duration of SLE was significantly longer (p = 0.0004) among patients with elevated anti-C1-INH levels compared with patients without this autoantibody (median disease duration 8 vs. 17 years, respectively). Anti-C1-INH level was not correlated with any other laboratory parameter or organ manifestation of the disease. These findings indicate that the anti-C1-INH level is higher in SLE patients than in healthy controls and furthermore, the anti-C1-INH level correlates with the duration and activity of the disease.

Original languageEnglish
Pages (from-to)634-638
Number of pages5
JournalLupus
Volume19
Issue number5
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Systemic Lupus Erythematosus
Autoantibodies
Hereditary Angioedemas
Complement C4
Blood Sedimentation
Serum
C-Reactive Protein
Multicenter Studies
Immunoglobulin G
Antibodies
DNA

Keywords

  • Anti-C1-inhibitor
  • Anti-C1q
  • Complement
  • Disease activity marker
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology

Cite this

C1-inhibitor autoantibodies in SLE. / Mészáros, T.; Füst, G.; Farkas, H.; Jakab, L.; Temesszentandrási, G.; Nagy, G.; Kiss, E.; Gergely, P.; Zeher, M.; Griger, Z.; Czirják, L.; Hóbor, R.; Haris, A.; Polner, K.; Varga, L.

In: Lupus, Vol. 19, No. 5, 04.2010, p. 634-638.

Research output: Contribution to journalArticle

Mészáros, T, Füst, G, Farkas, H, Jakab, L, Temesszentandrási, G, Nagy, G, Kiss, E, Gergely, P, Zeher, M, Griger, Z, Czirják, L, Hóbor, R, Haris, A, Polner, K & Varga, L 2010, 'C1-inhibitor autoantibodies in SLE', Lupus, vol. 19, no. 5, pp. 634-638. https://doi.org/10.1177/0961203309357059
Mészáros T, Füst G, Farkas H, Jakab L, Temesszentandrási G, Nagy G et al. C1-inhibitor autoantibodies in SLE. Lupus. 2010 Apr;19(5):634-638. https://doi.org/10.1177/0961203309357059
Mészáros, T. ; Füst, G. ; Farkas, H. ; Jakab, L. ; Temesszentandrási, G. ; Nagy, G. ; Kiss, E. ; Gergely, P. ; Zeher, M. ; Griger, Z. ; Czirják, L. ; Hóbor, R. ; Haris, A. ; Polner, K. ; Varga, L. / C1-inhibitor autoantibodies in SLE. In: Lupus. 2010 ; Vol. 19, No. 5. pp. 634-638.
@article{fb5202e527dc45438e6defde6c59250f,
title = "C1-inhibitor autoantibodies in SLE",
abstract = "The presence of anti-C1-inhibitor (anti-C1-INH) autoantibodies is a hallmark of acquired C1-inhibitor deficiency. However, only scarce data are available on their prevalence, diagnostic value, and/or significance in systemic lupus erythematosus (SLE). In a multicentre study, we determined the levels of autoantibodies to C1-inhibitor in sera from 202 patients with SLE and 134 healthy controls. Additional clinical and laboratory parameters, such as organ involvement, as well as anti-C1q, anti-double-stranded DNA antibody, erythrocyte sedimentation rate, C-reactive protein, C3 and C4 serum complement levels have been studied in patients. The level of anti-C1-INH IgG was significantly higher (p = 0.034) in SLE patients, than in the controls. A high anti-C1-INH level of ĝ‰¥0.4 U/ml (mean of controls + 2 SD) was found in 17{\%} of the patients, but in only 4{\%} of the controls (p = 0.0003). The SLEDAI score was significantly higher (p = 0.048) and the duration of SLE was significantly longer (p = 0.0004) among patients with elevated anti-C1-INH levels compared with patients without this autoantibody (median disease duration 8 vs. 17 years, respectively). Anti-C1-INH level was not correlated with any other laboratory parameter or organ manifestation of the disease. These findings indicate that the anti-C1-INH level is higher in SLE patients than in healthy controls and furthermore, the anti-C1-INH level correlates with the duration and activity of the disease.",
keywords = "Anti-C1-inhibitor, Anti-C1q, Complement, Disease activity marker, Systemic lupus erythematosus",
author = "T. M{\'e}sz{\'a}ros and G. F{\"u}st and H. Farkas and L. Jakab and G. Temesszentandr{\'a}si and G. Nagy and E. Kiss and P. Gergely and M. Zeher and Z. Griger and L. Czirj{\'a}k and R. H{\'o}bor and A. Haris and K. Polner and L. Varga",
year = "2010",
month = "4",
doi = "10.1177/0961203309357059",
language = "English",
volume = "19",
pages = "634--638",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - C1-inhibitor autoantibodies in SLE

AU - Mészáros, T.

AU - Füst, G.

AU - Farkas, H.

AU - Jakab, L.

AU - Temesszentandrási, G.

AU - Nagy, G.

AU - Kiss, E.

AU - Gergely, P.

AU - Zeher, M.

AU - Griger, Z.

AU - Czirják, L.

AU - Hóbor, R.

AU - Haris, A.

AU - Polner, K.

AU - Varga, L.

PY - 2010/4

Y1 - 2010/4

N2 - The presence of anti-C1-inhibitor (anti-C1-INH) autoantibodies is a hallmark of acquired C1-inhibitor deficiency. However, only scarce data are available on their prevalence, diagnostic value, and/or significance in systemic lupus erythematosus (SLE). In a multicentre study, we determined the levels of autoantibodies to C1-inhibitor in sera from 202 patients with SLE and 134 healthy controls. Additional clinical and laboratory parameters, such as organ involvement, as well as anti-C1q, anti-double-stranded DNA antibody, erythrocyte sedimentation rate, C-reactive protein, C3 and C4 serum complement levels have been studied in patients. The level of anti-C1-INH IgG was significantly higher (p = 0.034) in SLE patients, than in the controls. A high anti-C1-INH level of ĝ‰¥0.4 U/ml (mean of controls + 2 SD) was found in 17% of the patients, but in only 4% of the controls (p = 0.0003). The SLEDAI score was significantly higher (p = 0.048) and the duration of SLE was significantly longer (p = 0.0004) among patients with elevated anti-C1-INH levels compared with patients without this autoantibody (median disease duration 8 vs. 17 years, respectively). Anti-C1-INH level was not correlated with any other laboratory parameter or organ manifestation of the disease. These findings indicate that the anti-C1-INH level is higher in SLE patients than in healthy controls and furthermore, the anti-C1-INH level correlates with the duration and activity of the disease.

AB - The presence of anti-C1-inhibitor (anti-C1-INH) autoantibodies is a hallmark of acquired C1-inhibitor deficiency. However, only scarce data are available on their prevalence, diagnostic value, and/or significance in systemic lupus erythematosus (SLE). In a multicentre study, we determined the levels of autoantibodies to C1-inhibitor in sera from 202 patients with SLE and 134 healthy controls. Additional clinical and laboratory parameters, such as organ involvement, as well as anti-C1q, anti-double-stranded DNA antibody, erythrocyte sedimentation rate, C-reactive protein, C3 and C4 serum complement levels have been studied in patients. The level of anti-C1-INH IgG was significantly higher (p = 0.034) in SLE patients, than in the controls. A high anti-C1-INH level of ĝ‰¥0.4 U/ml (mean of controls + 2 SD) was found in 17% of the patients, but in only 4% of the controls (p = 0.0003). The SLEDAI score was significantly higher (p = 0.048) and the duration of SLE was significantly longer (p = 0.0004) among patients with elevated anti-C1-INH levels compared with patients without this autoantibody (median disease duration 8 vs. 17 years, respectively). Anti-C1-INH level was not correlated with any other laboratory parameter or organ manifestation of the disease. These findings indicate that the anti-C1-INH level is higher in SLE patients than in healthy controls and furthermore, the anti-C1-INH level correlates with the duration and activity of the disease.

KW - Anti-C1-inhibitor

KW - Anti-C1q

KW - Complement

KW - Disease activity marker

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=77951226069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951226069&partnerID=8YFLogxK

U2 - 10.1177/0961203309357059

DO - 10.1177/0961203309357059

M3 - Article

C2 - 20071476

AN - SCOPUS:77951226069

VL - 19

SP - 634

EP - 638

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 5

ER -